The FDA recently, amidst some serious controversy approved an anti-amyloid-beta human monoclonal antibody, Aducanumab (Aduhelm) for the treatment of Alzheimer’s disease. The new treatment approved after 2003 is the first to target beta-amyloid to slow down the progression of AD. The results of three distinct randomized, dose-ranging studies (a total of 3382 patients) demonstrated time and dose dependent reduction of beta amyloid in the treatment group compared to controls. The Alzheimer’s Association bolsters the FDA approval since the clinical trial results also demonstrated a 22% dip in cognitive and function decline. The drug could mean more quality time and slow cognitive decline in early diagnosis.
